<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276691</url>
  </required_header>
  <id_info>
    <org_study_id>AsprinFire2011</org_study_id>
    <nct_id>NCT01276691</nct_id>
  </id_info>
  <brief_title>Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting</brief_title>
  <official_title>Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal Emergency Management Agency</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Urbana-Champaign</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that

        1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet
           activation, platelet aggregation, and clotting potential, b) increased fibrinolytic
           potential following fire fighting, c) no significant effect on endothelial function or
           arterial stiffness versus the placebo condition.

        2. chronic treatment with low-dose aspirin will lead to a) decreased resting and fire
           fighting induced platelet activation, platelet aggregation, clotting potential, b)
           increased fibrinolytic potential, and c) increased endothelial function and decreased
           arterial stiffness in response to live fire fighting versus the placebo condition.

        3. short-term fire fighting activity will result in: a) a reduction in arterial function
           (reduced endothelial function, increased augmentation index and an attenuated arterial
           stiffness response); b) a disruption in hemostasis that is characterized by an increase
           in platelet number and function, an increased coagulatory potential and altered
           fibrinolytic potential; and c) an elevation in procoagulatory cytokines, systemic
           inflammation, monokine chemoattractant protein, and matrix metalloproteinases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>Less than 60 minutes before initiating firefighting activity</time_frame>
    <description>Vascular function will be assessed via pulse wave analysis, pulse wave velocity, carotid artery compliance, beta stiffness index, forearm rsistance artery vasodilatory capacity, and brachial artery blood flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostatic balance</measure>
    <time_frame>Less than 60 minutes before initiating firefighting activity</time_frame>
    <description>Blood samples will be collected by a trained phlebotomist from the antecubital vein directly into vacutainers with little or no stasis using a 21-gauge needle. Samples will be used to quantify platetlet number and function, fibrinogen, prothrombin and partial thromboplastin time, t-PA and PAI-1 activities and antigen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory and Oxidative Stress markers</measure>
    <time_frame>Less than 60 minutes before initiating firefighting activity</time_frame>
    <description>CRP,Intercellular adhesion molecule (ICAM)-1, IL-6, MMP-9, TIMP-1, TIMP-2,8-iso-prostaglandin F2a, soluble P-selectin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>Less than 60 minutes after completing 20 minutes of firefighting activity</time_frame>
    <description>Vascular function will be assessed via pulse wave analysis, pulse wave velocity, carotid artery compliance, beta stiffness index, forearm rsistance artery vasodilatory capacity, and brachial artery blood flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostatic balance</measure>
    <time_frame>Less than 60 minutes after completing 20 minutes of firefighting activity</time_frame>
    <description>Blood samples will be collected by a trained phlebotomist from the antecubital vein directly into vacutainers with little or no stasis using a 21-gauge needle. Samples will be used to quantify platetlet number and function, fibrinogen, prothrombin and partial thromboplastin time, t-PA and PAI-1 activities and antigen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory and Oxidative Stress markers</measure>
    <time_frame>Less than 60 minutes after completing 20 minutes of firefighting activity</time_frame>
    <description>CRP,Intercellular adhesion molecule (ICAM)-1, IL-6, MMP-9, TIMP-1, TIMP-2,8-iso-prostaglandin F2a, soluble P-selectin</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>C.Medical Procedure; Vascular, Functional or Late</condition>
  <condition>Hemostatic Balance</condition>
  <arm_group>
    <arm_group_label>Acute, Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acute single dosage of placebo provided 30 minutes prior to firefighting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic, Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>81 mg asprin provided prior to firefighting- 14 day dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14 day dosage of placebo provided prior to firefighting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>81 mg enteric coated aspirin</intervention_name>
    <description>81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting</description>
    <arm_group_label>Acute, Aspirin</arm_group_label>
    <arm_group_label>Acute, Placebo</arm_group_label>
    <arm_group_label>Chronic, Aspirin</arm_group_label>
    <arm_group_label>Chronic, Placebo</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male firefighters (career and volunteer), medically cleared by home fire department.

          -  Ages 40 - 60

          -  Completion of a yearly period medical evaluation based on NFPA 1582 within the past 12
             months or an evaluation by an occupational medical group through this study.

        Exclusion Criteria:

          -  Over 60 or under 40 years of age.

          -  Not a firefighter.

          -  Individuals at risk for developing gastrointestinal (GI) complications while on
             aspirin therapy due to a combination of the following: smoking; concurrent NSAID,
             steroid, Clopidogrel, or Warfarin therapy; history of upper GI complications; history
             of renal impairment; history of elevated serum creatinine; hypertension; and cardiac
             failure.

          -  Individuals with cases of allergy or asthma, intolerance, and recurrent vascular
             events.

          -  Individuals taking statins.

          -  Individuals who are currently taking aspiring regularly.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gavin P Horn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois Urbana-Champaign</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illinois Fire Service Institute</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fsi.illinois.edu</url>
    <description>Illinois Fire Service Institute home page</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Urbana-Champaign</investigator_affiliation>
    <investigator_full_name>Gavin Horn</investigator_full_name>
    <investigator_title>Senior Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Vascular function</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Hemostatic balance</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Firefighting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

